Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial Jeffrey S. Weber , Sandra P. D’Angelo , David R. Minor +25 more 2015 The Lancet Oncology 2617 citations